



Monaldi Archives for Chest Disease

eISSN 2532-5264

<https://www.monaldi-archives.org/>

Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The **Early Access** service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community.

These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Monaldi Archives for Chest Disease** is, therefore, e-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

All legal disclaimers applicable to the journal apply to this production process as well.

Monaldi Arch Chest Dis 2023 [Online ahead of print]

To cite this Article:

Garg S, Upadhyaya P, Kumar A, et al. **Overcoming the challenges of a misdiagnosed rare lung disease - Idiopathic pleuroparenchymal fibroelastosis.** *Monaldi Arch Chest Dis* doi: 10.4081/monaldi.2023.2632

 ©The Author(s), 2023
Licensee [PAGEPress](https://www.pagepress.org/), Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.



Overcoming the challenges of a misdiagnosed rare lung disease - Idiopathic pleuroparenchymal fibroelastosis

Shivam Garg,¹ Pratap Upadhy,¹ Arul Kumar,¹ Norton Stephen,² Bala Subramanian¹

¹Department of Pulmonary Medicine; ²Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

Corresponding author: Dr. Pratap Upadhy, Associate professor, Department of Pulmonary Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Dhanavantari nagar, Puducherry 605006, India. E-mail: drpratapujipmer@gmail.com

Conflict of interest: The authors declare that they have no competing interests, and all authors confirm accuracy.

Contribution: Resources, data curation, writing- original draft: SG, PU, AK, BS, NS; Investigation: SG, PU, AK, NS; Writing – review & editing: SG, PU; Supervision: PU; Visualisation: SG, PU.

Availability of data and materials: All data underlying the findings are fully available.

Ethics approval and consent to participate: No ethical committee approval was required for this case report by the Department. Informed consent was obtained from the patient included in the study.

Patient consent for publication: The patient gave his written permission to use his data to publish this case report and any accompanying images.

Abstract

Pleuroparenchymal fibroelastosis (PPFE) is a rare condition characterized by pleural and subpleural lung fibroelastosis with an upper lobe predominance. We present the third case of idiopathic pleuroparenchymal fibroelastosis (IPPF) from India, as well as the second antemortem diagnosis. A 27-year-old man presented with a one-year history of mMRC class II dry cough and shortness of breath. He described a fifteen-kilogram weight loss. After a clinico-radiological diagnosis, he was given anti-tubercular treatment and referred because he showed no improvement. A high-resolution computed tomography of the chest revealed bilateral upper lobe bullae, parenchymal and subpleural fibrosis, and irregular pleural thickening. PPFE was found in surgical lung and pleural biopsies. He was given systemic glucocorticoids but did not respond clinically or radiologically. Pirfenidone and a lung transplant were out of reach for him. He died nine months after being diagnosed with his condition. Finally, IPPF is an extremely rare entity, with only three cases reported from our subcontinent. As a result, it is easily underdiagnosed or misdiagnosed; clinician awareness of this condition is critical for better diagnosis and management.

Key words: Idiopathic pleuroparenchymal fibroelastosis; pulmonary tuberculosis; pectus excavatum.

Introduction

Pleuroparenchymal fibroelastosis (PPFE) is an under and misdiagnosed clinicopathological entity characterized by fibroelastosis of the pleura and subpleural lung parenchyma with striking upper lobe predominance. Multiple sporadic cases and case series have been reported from all over the globe [1-6]. To the best of our knowledge, this is the third case of idiopathic pleuroparenchymal fibroelastosis (IPPF) to be reported from our subcontinent and the second case for which the diagnosis was made antemortem. If not appropriately evaluated, it can be misdiagnosed as fibrotic Hypersensitivity-pneumonitis, pulmonary tuberculosis, or pulmonary tuberculosis complications [7]. Here, we present a case of a 27-year-old male misdiagnosed with pulmonary tuberculosis and later found to have IPPF.

Case Report

A 27-year-old male electrician presented to us in September 2022 with a dry cough and shortness of breath as per the modified Medical Research Council (mMRC) functional class II, of one-year duration. There was no history of fever or chest pain. He gave a history of loss of

appetite and fifteen-kilogram weight in 6 months. He denied any history of alcohol consumption or smoking. There was no history of exposure to animals, birds, inorganic dust, skin rash, or joint pain. His past history was significant for anti-tubercular drug (four-drug regimen) intake from January to June 2022 after a chest roentgenogram diagnosis without microbiological confirmation. As the patient had no symptomatic improvement with anti-tubercular treatment, the patient was referred to our institute for further evaluation.

On general examination, he was thin, cachectic with a body mass index of 11.1 kg/m², tachypnoeic, with pectus excavatum (Figure 1). Chest auscultation revealed decreased breath sounds bilaterally with fine end-inspiratory crepitations more in bilateral infraclavicular and suprascapular areas. Arterial blood analysis showed pH 7.46, pCO₂ 24, pO₂ 96.4, HCO₃ 19.2, and SO₂ 97.9. A complete hemogram revealed a haemoglobin level of 10.3 g/dL, total leucocyte counts of 6,350/microlitre, and platelet count of 254,000/microlitre. Hepatic, renal, and thyroid function tests were reported normal. His erythrocyte sedimentation rate and C-reactive protein were 8 mm/hour and 2 mg/L, respectively. A chest roentgenogram showed bilateral upper zone cystic changes with right-side pleural thickening with costophrenic angle blunting and cardiac shift to the left side (Figure 2).

High-resolution computed tomography of the chest showed bilateral upper lobe bullae with parenchymal and subpleural fibrosis and volume loss with irregular pleural thickening and Haller index (ratio of thoracic width and height, measured from axial CT) of 6.7 (Figure 3). On pulmonary function test: spirometry was consistent with a severe restrictive pattern with forced expiratory volume in 1 second (FEV₁)/forced vital capacity (FVC) ratio of 88.9% with decreased FEV₁ 1.6 L, 45% and FVC 1.8 L, 40%. Given clinical, physiological, and radiological findings, differential diagnoses of familial idiopathic pulmonary fibrosis, advanced pulmonary sarcoidosis, post-tuberculosis fibrothorax, fibrotic hypersensitivity pneumonitis, pulmonary apical fibrocystic disease secondary to ankylosing spondylitis, and idiopathic pleuroparenchymal fibroelastosis were made. The patient did not give a history of any similar illness in his family members. He did not have any features suggestive of connective tissue disorder, and his serum anti-nuclear antibodies and rheumatoid factor were negative, ruling out connective tissue disease-associated interstitial lung disease. Due to the uncertainty in diagnosis and non-availability of video-assisted thoracoscopic surgery, a surgical lung biopsy was done by the cardiothoracic surgery team. On histopathology, sections from the left upper lobe showed dense collagenous fibrosis composed of hyalinized collagen and fibroelastic foci with minimal inflammation (Figure 4). Adjacent preserved lung parenchyma showed intra-alveolar hemosiderin-laden macrophages. Sections from the left

lung pleura showed dense collagenous fibrosis composed of hyalinized collagen with associated reactive mesothelial hyperplasia (Figure 5). Masson trichome special stain highlighted collagenous tissue in the section from lung parenchyma and pleural tissue. The patient developed left-sided pneumothorax postoperatively, for which tube thoracostomy was done with a 16 French catheter under local anaesthesia. Post tube thoracostomy, the lung did not expand (Figure 6). With a diagnosis of idiopathic pleuroparenchymal fibroelastosis, the patient was started on systemic glucocorticoids empirically, even though its benefits are unproven. There was no clinical or radiological response after 1 month. The patient was offered treatment with pirfenidone and counselled for a lung transplant, but he was not willing to either due to financial restraints. As the patient had severe pectus excavatum, surgical correction was also advised, but the patient was not willing for that either. The patient succumbed to his condition after nine months of diagnosis.

Discussion

The American Thoracic Society/European Respiratory Society recognized IPPFE as a separate entity in 2013, but the description of IPPFE in literature goes back to 1992 when Amitani *et al.* reported 13 cases of pulmonary fibrosis localised to the upper lobe and named this entity Idiopathic pulmonary upper lobe fibrosis [8]. Later, in 2004, Frankel *et al.* coined the term idiopathic pleuroparenchymal fibroelastosis [9]. The first case in the Indian subcontinent was reported in 2015 by Thangakunam *et al.*, where the diagnosis was made *post-mortem* [1]. Maturu *et al.*, in 2019, reported the first case in which the diagnosis was established antemortem in our subcontinent [2].

In addition to IPPFE, multiple systemic conditions, most commonly hematopoietic stem or lung transplantation; chronic hypersensitivity pneumonitis; autoimmune or connective tissue disease, and occupational exposure to aluminium and asbestos, are associated with PPFE [10-13]. In a case series by Reddy *et al.*, recurrent infections accounted for PPFE in half the cases [14].

As surgical lung biopsy (SLB) is not always feasible, Watanabe *et al.* proposed three conditions for a diagnosis of PPFE without SLB: i) radiologically possible, ii) radiologically probable, and iii) radiologically and physiologically probable [15]. Radiological criteria for definite PPFE include pleural thickening with subpleural fibrosis in the upper lobes and minimal lower lobe involvement [14]. In our patient, bilateral upper lobe bullae with parenchymal and subpleural fibrosis and volume loss with irregular pleural thickening were present, predominantly in the upper lobes.

Clinical features vary, most commonly being dyspnoea and dry cough. Spontaneous pneumothorax or pneumomediastinum has also been reported [16]. The mechanism underlying spontaneous pneumothorax or iatrogenic pneumothorax has yet to be completely understood. It has been postulated that elastic pleura offers low resistance to tear. Moreover, tissue affected after surgery may exhibit a limited healing capacity which in turn leads to persistent bronchopleural fistulae [17]. Our patient developed pneumothorax and bronchopleural fistulae post-operatively.

Progressive weight loss is also reported during the course of the disease, which may arouse suspicion of an occult malignancy or superadded infection, such was the case in our patient. Our patient, being from a Tuberculosis prevalent country, presented with a chronic history of dyspnoea and cough with significant weight loss and involvement of the upper lobe in imaging; he was naturally suspected of having *Mycobacterium tuberculosis* infection and was started on treatment for the same. No response to the treatment probed further investigation, leading to the diagnosis of IPPFE.

Currently, there is no consensus on treating IPPFE except for supportive care and, ultimately, lung transplantation. However, low-dose prednisolone may have a useful, although unproven immunomodulatory effect [18] In a case report by Sato *et al.*, pirfenidone has shown to prevent the decline in pulmonary function in IPPFE patients [19]. Nintedanib may also prevent FVC decline in IPPFE, as demonstrated by the case series by Naseer *et al.* [20].

In conclusion, IPPFE is a very rare entity, with just three cases reported from our subcontinent. Thus, it can be easily underdiagnosed or misdiagnosed, probably due to a lack of knowledge and awareness of this entity. Our case of IPPFE was first misdiagnosed as pulmonary tuberculosis. IPPFE should be considered as a differential diagnosis in patients with predominantly upper lobe pulmonary fibrosis. Awareness of this condition among clinicians is essential for better diagnosis and management.

References

1. Thangakunam B, Isaac BTJ, Christopher DJ, Burad D. Idiopathic pleuroparenchymal fibroelastosis – A rare idiopathic interstitial pneumonia. *Respir Med Case Rep* 2016;17:8-11.
2. Maturu VN, Rajendran P, Narahari NK. Idiopathic pleuroparenchymal fibroelastosis presenting as bilateral spontaneous pneumothorax: A case report. *Lung India* 2019;36:75.
3. Bhaskar M, Tisekar O, Tandon S, et al. Rapidly progressive pleuro-parenchymal fibroelastosis secondary to cyclophosphamide chemotherapy. *Indian J Med Paediatr Oncol* 2020;41:427–9.
4. Fukada A, Suzuki Y, Mori K, et al. Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume. *Eur Respir J* 2022;60:2200637.
5. Kinoshita Y, Kushima H, Ishii H. Idiopathic pleuroparenchymal fibroelastosis. *BMJ Case Rep* 2022;15:e251483.
6. Kinoshita Y, Miyamura T, Ikeda T, et al. Limited efficacy of nintedanib for idiopathic pleuroparenchymal fibroelastosis. *Respir Investig* 2022;60:562–9.
7. Boerner EB, Costabel U, Wessendorf TE, et al. Idiopathic pleuroparenchymal fibroelastosis (PPFE) – A case study of a rare entity. *Rev Port Pneumol Engl Ed* 2017;23:352–5.
8. Amitani R. Idiopathic pulmonary upper lobe fibrosis (IPUF). *Kokyu* 1992;11:693.
9. Frankel SK, Cool CD, Lynch DA, Brown KK. Idiopathic pleuroparenchymal fibroelastosis: description of a novel clinicopathologic entity. *Chest* 2004;126:2007–13.
10. Konen E, Weisbrod GL, Pakhale S, et al. Fibrosis of the upper lobes: a newly identified late-onset complication after lung transplantation? *AJR Am J Roentgenol* 2003;181:1539–43.
11. Jacob J, Odink A, Brun AL, et al. Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis. *Respir Med* 2018;138:95–101.
12. Enomoto Y, Nakamura Y, Colby TV, et al. Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. *PLoS One* 2017;12:e0180283.
13. Xu L, Rassaei N, Caruso C. Pleuroparenchymal fibroelastosis with long history of asbestos and silicon exposure. *Int J Surg Pathol* 2018;26:190–3.
14. Reddy TL, Tominaga M, Hansell DM, et al. Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. *Eur Respir J* 2012;40:377–85.
15. Watanabe K, Ishii H, Kiyomi F, et al. Criteria for the diagnosis of idiopathic pleuroparenchymal fibroelastosis: A proposal. *Respir Investig* 2019;57:312–20.
16. Cuppens K, Verbeken E, Coolen J, et al. Idiopathic pleuroparenchymatous fibroelastosis: A case report and brief review of the literature. *Respir Med Case Rep* 2014;12:7–9.
17. Becker CD, Gil J, Padilla ML. Idiopathic pleuroparenchymal fibroelastosis: an unrecognized or misdiagnosed entity? *Mod Pathol* 2008;21:784–7.
18. Shioya M, Otsuka M, Yamada G, et al. Poorer prognosis of idiopathic pleuroparenchymal fibroelastosis compared with idiopathic pulmonary fibrosis in advanced stage. *Can Respir J* 2018;2018:6043053.

19. Sato S, Hanibuchi M, Takahashi M, et al. A patient with idiopathic pleuroparenchymal fibroelastosis showing a sustained pulmonary function due to treatment with pirfenidone. *Intern Med* 2016;55:497–501.
20. Nasser M, Chebib N, Philit F, et al. Treatment with nintedanib in patients with pleuroparenchymal fibroelastosis. *Eur Respir J* 2017;50:PA4876.



Figure 1. Anterior chest showing pectus excavatum.



Figure 2. Chest roentgenogram posteroanterior view showing bilateral upper zone cystic changes with right side pleural thickening with costophrenic angle blunting and cardiac shift to the left side.




Figure 3. Transversal computed tomography of chest showing a) bilateral pleural thickening; b) bilateral upper lobe bullous changes with interlobular septal thickening; c) severe pectus excavatum with Haller index of 6.7.




Figure 4. a) Section from lung biopsy shows sheets of collagenous fibrosis replacing the normal lung parenchyma with compressed normal alveolar spaces (H and E, x200). b) Masson trichrome special stain highlighting the collagenous fibrosis (x200).




Figure 5. a) Section from the pleura shows extensive areas of collagenous fibrosis with focal mesothelial cell hyperplasia (H and E, x200). b) At higher magnification (x400), highlighting foci of mesothelial hyperplasia. c) Masson trichrome special stain in the pleural tissue highlighting the collagenous fibrosis (x200).



Figure 6. Chest radiograph posteroanterior view postoperatively, showing left side pneumothorax (left panel) and non-expansion of lung post-tube thoracostomy (right panel).